Inventor
DUBOWCHIK GENE M
US31 patents
⚠️ This page may combine multiple inventors who share the name “DUBOWCHIK GENE M”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BRISTOL MYERS SQUIBB CO
27 patentsUS6759509B1Jul 6, 2004
Branched peptide linkers
BRISTOL MYERS SQUIBB CO217 citations98
US7569578B2Aug 4, 2009
Heterocyclic anti-migraine agents
BRISTOL MYERS SQUIBB CO14 citations84
US7842808B2Nov 30, 2010
Anti-migraine spirocycles
BRISTOL MYERS SQUIBB CO13 citations83
US7772244B2Aug 10, 2010
Therapeutic agents for the treatment of migraine
BRISTOL MYERS SQUIBB CO12 citations83
US7314883B2Jan 1, 2008
Anti-migraine treatments
BRISTOL MYERS SQUIBB CO12 citations83
US10266578B2Apr 23, 2019
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
BRISTOL MYERS SQUIBB CO9 citations82
US7754732B2Jul 13, 2010
Spirocyclic anti-migraine compounds
BRISTOL MYERS SQUIBB CO13 citations82
US6515005B2Feb 4, 2003
Substituted azole derivatives as inhibitors of corticotropin releasing factor
BRISTOL MYERS SQUIBB CO13 citations82
US7220862B2May 22, 2007
Calcitonin gene related peptide receptor antagonists
BRISTOL MYERS SQUIBB CO11 citations81
US7244746B2Jul 17, 2007
Imidazolyl derivatives as corticotropin releasing factor inhibitors
BRISTOL MYERS SQUIBB CO9 citations74
US10752609B2Aug 25, 2020
GSK-3 inhibitors
BRISTOL MYERS SQUIBB CO6 citations72
US9718804B2Aug 1, 2017
GSK-3 inhibitors
BRISTOL MYERS SQUIBB CO5 citations72
US6888004B2May 3, 2005
Imidazolyl derivatives as corticotropin releasing factor inhibitors
BRISTOL MYERS SQUIBB CO7 citations71
US7125990B2Oct 24, 2006
Imidazolyl derivatives as corticotropin releasing factor inhibitors
BRISTOL MYERS SQUIBB CO3 citations63
US11053258B2Jul 6, 2021
Pyrimidine carboxamides as GSK-3 inhibitors
BRISTOL MYERS SQUIBB CO0 citations62
US7238699B2Jul 3, 2007
Imidazolyl derivatives as corticotropin releasing factor inhibitors
BRISTOL MYERS SQUIBB CO3 citations62
US6908931B2Jun 21, 2005
Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists
BRISTOL MYERS SQUIBB CO5 citations62
US6239146B1May 29, 2001
Neurotrophic difluoroamide agents
BRISTOL MYERS SQUIBB CO2 citations62
US6096762AAug 1, 2000
Neurotrophic difluoroamide agents
BRISTOL MYERS SQUIBB CO4 citations62
US12097241B2Sep 24, 2024
Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides
BRISTOL MYERS SQUIBB CO0 citations61
US12097242B2Sep 24, 2024
Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides
BRISTOL MYERS SQUIBB CO0 citations61
US11364281B2Jun 21, 2022
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof
BRISTOL MYERS SQUIBB CO0 citations61
US11185570B2Nov 30, 2021
Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides
BRISTOL MYERS SQUIBB CO0 citations61
US6228872B1May 8, 2001
Neurotrophic diamide and carbamate agents
BRISTOL MYERS SQUIBB CO3 citations57
US10774086B2Sep 15, 2020
GSK-3 inhibitors
BRISTOL MYERS SQUIBB CO0 citations51
US7470680B2Dec 30, 2008
Constrained compounds as CGRP-receptor antagonists
BRISTOL MYERS SQUIBB CO1 citations51
US9809573B2Nov 7, 2017
Substituted pyridine derivatives useful as GSK-3 inhibitors
BRISTOL MYERS SQUIBB CO0 citations41